A double-blind, double dummy, randomized parallel design trial to evaluate the effects of 12 weeks of treatment with 300 mg aliskiren compared to 5 mg amlodipine on insulin resistance and coronary endothelial function in hypertensive patients with metabolic syndrome.

Trial Profile

A double-blind, double dummy, randomized parallel design trial to evaluate the effects of 12 weeks of treatment with 300 mg aliskiren compared to 5 mg amlodipine on insulin resistance and coronary endothelial function in hypertensive patients with metabolic syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2011

At a glance

  • Drugs Aliskiren; Amlodipine
  • Indications Glucose intolerance; Hypertension; Insulin resistance; Metabolic syndrome; Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
    • 27 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top